Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amubarvimab + Romlusevimab to enhance SARS-CoV-2 specific immunity in immunocompromised adults after booster vaccination
ChiCTR2200062351Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial in coronavirus disease 2019 (COVID-19) comparing Amubarvimab + Romlusevimab with Placebo (2 arms). Primary endpoint: Neutralizing activity of serum against SARS-CoV-2. Planned start May 2022; status: not yet recruiting.
02
Drugs
amubarvimabromlusevimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2200062351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062351.